Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
36,387,318
-
Share change
-
+424,607
-
Total reported value
-
$270,401,264
-
Put/Call ratio
-
47%
-
Price per share
-
$7.43
-
Number of holders
-
109
-
Value change
-
+$4,422,709
-
Number of buys
-
52
-
Number of sells
-
59
Institutional Holders of JOUNCE THERAPEUTICS INC - COM (JNCE) as of Q3 2021
As of 30 Sep 2021,
JOUNCE THERAPEUTICS INC - COM (JNCE) was held by
109 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
36,387,318 shares.
The largest 10 holders included
PFM Health Sciences, LP, TRV GP III, LLC, TRV GP II, LLC, ORBIMED ADVISORS LLC, BlackRock Inc., ADAGE CAPITAL PARTNERS GP, L.L.C., Logos Global Management LP, CITADEL ADVISORS LLC, VANGUARD GROUP INC, and RTW INVESTMENTS, LP.
This page lists
109
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.